Evercore Stock - Search News

Evercore ISI lifts CRISPR stock rating, target

TTD Stock Insight: Evercore Slaps with Rating Downgrade and Price Target Trim

Five-star-rated analyst Mark Mahaney at Evercore ISI has downgraded his rating from Buy to Hold on The Trade Desk (TTD) after the company

Hosted on MSN · 15h

Evercore ISI lifts CRISPR stock rating, target to $99

Evercore ISI analysts upgraded CRISPR Therapeutics stock from an In Line to an Outperform rating and increased the price target significantly to $99 from the previous $60. The upgrade comes as Evercore ISI anticipates pivotal developments that could mark the beginning of a transformative period for the company.

ETF Daily News · 22h

TXNM Energy (NYSE:TXNM) Stock Rating Upgraded by Evercore ISI

Evercore ISI upgraded shares of TXNM Energy (NYSE:TXNM – Free Report) from an in-line rating to an outperform rating in a report issued on Tuesday morning, MarketBeat.com reports. The brokerage currently has $54.

Business Insider · 17h

Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI

Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60.

Hosted on MSN · 2d

Evercore ISI cuts Lyft stock price target to $15 from $19

Evercore ISI made an adjustment to its price target for Lyft stock (NASDAQ:LYFT), reducing it to $15.00 from the previous $19.00, while keeping the rating at 'In Line'. The revision follows Lyft's mixed and lower-than-expected financial results for the fourth quarter.

14h

CRISPR upped to outperform by Evercore on upcoming data

Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

Evercore ISI Pounds the Table on Nvidia (NVDA) Stock Ahead of Earnings

Wall Street investment bank Evercore ISI (EVR) is pounding the table on Nvidia (NVDA) stock ahead of the chipmaker’s upcoming ...

21h

Evercore ISI Issues Positive Forecast for Confluent (NASDAQ:CFLT) Stock Price

Confluent (NASDAQ:CFLT – Get Free Report) had its target price upped by Evercore ISI from $32.00 to $40.00 in a report ...

13hon MSN

CRISPR Therapeutics stock rises following analyst upgrade

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.

Nvidia's Big Moment: Why This Sell-Off Could Be the Best Buying Opportunity of 2024

Investors are jittery over three big concernsChina's DeepSeek shaking up AI demand, a potential shift from GPUs to ASICs, and ...

Benzinga.com2d

1NVDA : Nvidia A Strong Buy With 42% Upside, Says Analyst Predicting 'Positive...

What Happened: In a client note on Sunday, analyst Mark Lipacis and his team at Evercore ISI added the chip giant to its ‘tactical outperform’ list. The firm has a $190 price target on the stock ...

Investing4d

Evercore sees a buying opportunity in Nvidia stock after DeepSeek sell-off

Investing.com -- The recent sell-off in Nvidia (NASDAQ: NVDA) stock, triggered by concerns over Chinese startup DeepSeek’s ...

3don MSN

Evercore’s Rich Ross explains why equities will see an ‘imminent’ breakout

Rich Ross, head of technical analysis at Evercore ISI, said that a breakout to an all-time high in the S&P 500 ( SP500 ), ( ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Evercore ISI lifts CRISPR stock rating, target

Related topics